Aberdeen Group
ODTX icon

Aberdeen Group’s Odyssey Therapeutics ODTX Stock Holding History

Aberdeen Group’s Portfolio ODTX Stock Details ODTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.78M Sell
79,944
-85,056
-52% -$1.81M ﹤0.01% 820
2026
Q2 		$3.09M Buy
+165,000
New +$2.89M ﹤0.01% 742

Other funds holding ODTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Lightspeed Management Company
Lightspeed Management Company Menlo Park, California $2.03B AUM 10.68% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Aberdeen Group's ODTX Position: Q3 2026 in Review

Aberdeen Group reduced its Odyssey Therapeutics (ODTX) stake by 52% in Q3 2026, selling an estimated $1.81M and leaving 79,944 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #820.

Aberdeen Group first reported a position in ODTX in Q2 2026 and has held it in 2 quarters since. The position peaked at $3.09M in Q2 2026. 41 funds tracked by Wall St. Rank hold ODTX as of Q3 2026.

  • Aberdeen Group held 79,944 shares of Odyssey Therapeutics worth $1.78M as of Q3 2026.
  • Aberdeen Group sold 85,056 Odyssey Therapeutics shares in Q3 2026, an estimated $1.81M.
  • Odyssey Therapeutics made up ﹤0.01% of Aberdeen Group's portfolio in Q3 2026, its #820 holding.
  • Aberdeen Group first reported a position in Odyssey Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Aberdeen Group's Odyssey Therapeutics position peaked at $3.09M in Q2 2026.
  • 41 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.